Investigating the C2 Modulation of the Imidazo[1,2‐a]pyrazine‐Based Hit Compound CTN1122: Synthesis, in vitro Antileishmanial Activity, Cytotoxicity and Casein Kinase 1 Inhibition

Documenti analoghi

• Investigating the C2 Modulation of the Imidazo[1,2-a]pyrazine-Based Hit Compound CTN1122: Synthesis, in vitro Antileishmanial Activity, Cytotoxicity and Casein Kinase 1 Inhibition.
  di: Tisseur, Lhana, et al.
  Pubblicazione: (2025)
• Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy.
  di: Tisseur, Lhana, et al.
  Pubblicazione: (2025)
• Late‐Stage Diversification of Pyrazoles as Antileishmanial Agents
  di: Tobias Winge, et al.
  Pubblicazione: (2024)
• Monodentate Phosphine Modulation in Cyclometallated Platinum(II) Complexes for Antileishmanial, Antiviral, and Antitumor Applications
  di: Antonio A. de Oliveira‐Neto, et al.
  Pubblicazione: (2025)
• Mechanochemical Approach for Metal‐Free Regioselective C5‐Sulfenylation of Imidazo[2,1‐b]Thiazoles
  di: Xinya Liu, et al.
  Pubblicazione: (2025)